We need to address the real reasons drug prices are higher in the U.S.— middlemen driving up prices for patients and foreign countries not paying their fair share. Our new ad urges lawmakers to crack down on the pharmacy benefit managers, stop the 340B hospital markups and ensure

Other wealthy countries underpay for innovative medicines—paying 60% less on average for brand medicines than they should. This is known as foreign freeriding, and it drives up costs for U.S. patients. It’s time to make other countries pay their fair share. More from @NPLB_org.

RT @PhRMA: Even as biopharma companies commit massive resources to R&D, the industry ranks in the middle for annual issued patents as compa….

Middlemen are driving up the cost of medicine in the U.S.—and patients are paying the price. #PBMs and #340B hospitals secure steep discounts on medicines but patients still have to pay the full price. If we want to lower costs for Americans, we need to rein in PBMs and fix the.

RT @statnews: Policymakers will need to address the true drivers of high drug prices here at home, while simultaneously pressing our allies….

RT @mybarra: Aluminum based adjuvants and thimerosal are the two ingredients often questioned in conversations about #vaccines but the evid….

Being part of an industry that's driving progress in research for diseases like Alzheimer’s is incredibly rewarding. Alzheimer’s doesn't just impact individuals, it affects entire families and communities. This month, I’m reflecting on the importance of the work we do to advance.

President Trump is right: Americans often overpay for medicine, and middlemen are cashing in, pocketing more in rebates and fees than the full prices of drugs in many other countries. Instead of implementing “foreign-first pricing,” here’s how I think we can lower drug prices for

At @semafor’s World Economy Summit, we explored how biopharma innovation is transforming public health, fueling economic growth, and poised to save billions in health care costs. The stakes—and the impact—have never been greater.

The FDA approval of @GileadSciences new medicine marks a transformative moment in the fight to end the #HIV epidemic. Congratulations to the Gilead team on this milestone.

The #340B program was meant to help patients, not pad hospital profits. But that's exactly what's happening in Ohio and across the country. New reporting adds to growing evidence that nonprofit hospitals exploit 340B markups while vulnerable patients see no benefit. Congress must.

UCB’s investment in U.S. biologics manufacturing reflects its growing footprint in the U.S. and ambition to bring its pipeline of innovative medicines to patients. This is a powerful commitment to innovation and patient access that will generate $5B in economic growth. Well done.

RT @ScottLaGanga: In this blog from @PhRMA, we see how the biopharmaceutical industry directly supports millions of jobs and contributes to….

Congratulations to Joaquin Duato and the rest of the @JNJNews team for launching their new Center for U.S. Healthcare Policy Research. America's robust, pro-innovation policies and gold-standard biopharmaceutical regulatory system allow it to stand out on the world’s stage. This.

Congratulations to @chipkahn on his well-earned retirement after 24 years at the helm of the @FAHhospitals. His sharp policy instincts, bipartisan leadership and steady hand during some of the most important health policy debates of our time have left a lasting impression. I’m.

Congratulations to Paul Hudson and the entire @Sanofi team for their continued commitment to investing in America. Their recent announcement to grow their R&D and manufacturing presence in the U.S., along with their new state-of-the-art collaborative workplace in Morristown, NJ,

The creativity and leadership of our PRIDE Umbrella, one of our employee resource groups, continually inspires me. Thank you for showing up, pushing for progress, and coordinating events that make our workplace more vibrant and inclusive. Throughout the month of June, PhRMA will

RT @PhRMA: Today, researchers from our member companies met with lawmakers on Capitol Hill to advocate for policies that protect biopharmac….

Under the IRA, patients are paying more, not less for prescription drugs. A new @PioneerBoston analysis shows a 32% hike in out-of-pocket costs for seniors for drugs subject to IRA price setting.